Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,538
datasets available to search
ShareScore release 0.9.0
Dataset results
2,538 results for “follow-up”
Data from: Gynaecological cancer follow-up: national survey of current practice in the UK
Objective: To establish a baseline of national practice for follow-up after treatment for gynaecological cancer. Design: Questionnaire survey. Setting: Gynaecological cancer centres and units. Geographical location: UK Participants: Members of the British Gynaecological Cancer Society and the National Forum of Gynaecological Oncology Nurses. Interventions: A questionnaire survey. Outcome measures: To determine schedules of follow-up, who provides it and what routine testing is used for patients who have had previous gynaecological cancer. Results: A total of 117 responses were obtained; 115 (98%) reported hospital scheduled regular follow-up appointments. Two involved General Practitioners. Follow-up was augmented or replaced by telephone follow-up in 29 (25%) and patient initiated appointments in 38 responses (32%). A total of 80 (68%) cancer specialists also offered combined follow-up clinics with other specialties. Clinical examinations for hospital based follow-up were mainly performed by doctors (67% for scheduled regular appointments and 63% for patient initiated appointments) while telephone follow-up care was provided in the majority by nurses (76%). Most respondents provided routine tests (76/117 (65%)), from which 66/76 (87%) reported carrying out surveillance tests for ovarian cancer, 35/76 (46%) for cervical cancer, 8/76 (11%) for vulval cancer and 7/76 (9%) for endometrial cancer. Usually patients were discharged after five years (82/117 (70%)), whereas three (3%) were discharged after four years, nine (8%) after three and one (1%) after two years. Conclusions: Practice varied but most used a standard hospital based protocol of appointments for five years and routine tests were performed usually for women with ovarian cancer. A minority utilised nurse-led or telephone follow-up. General Practitioners were rarely involved in routine care. A randomised study comparing various models of follow-up could be considered.
Data from: Sialendoscopy enhances salivary gland function in Sjögren's syndrome: a 6 month follow-up, randomized and controlled, single blind study
Objectives: To assess the effect of sialendoscopy of the major salivary glands on salivary flow and xerostomia in patients with Sjögren's syndrome (SS). Methods: Forty nine SS patients were randomly assigned to a control group (n=15) and two intervention groups: irrigation of the major glands with saline (n=16) or with saline followed by triamcinolone acetonide (TA) in saline (n=18). Unstimulated whole saliva flow (UWS), chewing stimulated whole saliva flow (SWS), citric-acid stimulated parotid flow (SPF), Clinical Oral Dryness Score (CODS), Xerostomia Inventory score (XI), and EULAR SS Patient Reported Index (ESSPRI) were obtained 1 week (T0) before, and 1(T1), 8(T8), 16(T16), and 24(T24) weeks after sialendoscopy. Results: Median baseline UWS, SWS and SPF scores were, respectively, 0.14, 0.46, and 0.22mL/min. After intervention, significant increases in UWS and SWS were observed in the saline group (at T8 (p=0.013) and T24 (p=0.004)) and the saline/TA group (at T24 (p=0.03) and T=16 (p=0.035). SPF was increased significantly in the saline/TA group at T24 (p=0.03). XI scores declined after sialendoscopy in both intervention groups. Compared to the control group, CODS, XI, and ESSPRI improved in the intervention groups. UWS, SWS, and SPF were higher in the intervention groups compared to the control group, but these differences were not significant except for SPF in the saline/TA group at T24 (p=0.005). Conclusions: Irrigation of the major salivary glands in SS patients enhances salivary flow and reduces xerostomia up to 6 months after sialendoscopy.
Data from: Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI center
Objective: To assess both short and long-term prognosis in consecutive patients with coronary heart disease (CHD) treated with drug-eluting stents (DES) in a high-volume percutaneous coronary intervention (PCI) center. Design: Observational cohort study. Setting: A hospital in the Henan province, China, between 2009 and 2011. Participants: A total of 2,533 patients were enrolled. Patients with ST-elevation myocardial infarction (STEMI) treated with urgent PCI accounted for 3.9% of cases; patients with STEMI treated with delayed PCI accounted for 20.5% of cases; patients with stable angina (SA) accounted for 16.5% of cases; and patients with non-ST elevation acute coronary syndromes (NSTE-ACS) accounted for 58.6% of cases. Primary outcomes: Death, major adverse cardiac and cerebrovascular events (MACCE: death/myocardial infarction/stroke), and target vessel revascularization. Results: Follow-up after a median of 29.8 months was obtained for 2,533 patients (92.6%). The mortality rate during hospitalization was highest in the urgent PCI group (p <0.001). During follow-up, although the incidences of death and MACCE were highest in the urgent PCI group, no significant differences were observed between the different groups. The incidences of cardiac death and myocardial infarction were significantly higher in the paclitaxel-eluting stent (PES) group than in the sirolimus-eluting stent (SES) group. Independent predictors of death during follow-up were: age, left ventricular ejection function (LVEF) < 40%, diabetes mellitus, prior coronary artery bypass graft (CABG), and chronic total occlusion. Conclusions: PCI patients with STEMI had the worst hospital and long-term prognosis. The mortality rate after hospital increased markedly in NSTE-ACS patients. SES seems to be more effective than PES.
Data from: Disruption of memory reconsolidation erases a fear memory trace in the human amygdala: An 18-month follow-up
Fear memories can be attenuated by reactivation followed by disrupted reconsolidation. Using functional magnetic resonance imaging we recently showed that reactivation and reconsolidation of a conditioned fear memory trace in the basolateral amygdala predicts subsequent fear expression over two days, while reactivation followed by disrupted reconsolidation abolishes the memory trace and suppresses fear. In this follow-up study we demonstrate that the behavioral effect persists over 18 months reflected in superior reacquisition after undisrupted, as compared to disrupted reconsolidation, and that neural activity in the basolateral amygdala representing the initial fear memory predicts return of fear. We conclude that disrupting reconsolidation have long lasting behavioral effects and may permanently erase an amygdala-dependent fear memory.
Follow-up for I-SCLET Pterygium Surgery
<p>Anonymized record of I-SCLET surgeries with follow-up performed by Dr. Porfirio Oliver.<br><br>Paper link: https://www.researchgate.net/publication/380492682_Intact_Superior_Conjunctival_Limbal_Epithelial_Transplant_I-SCLET_Pterygium_Surgery_Low_to_No_Recurrence_Case_Series_and_Perspective</p>
Data from: Incidence and risk factors of first-line antiretroviral treatment failure among human immunodeficiency virus-infected children in Amhara regional state, Ethiopia: a retrospective follow-up study
Objective: This study aimed to assess the incidence and risk factors of treatment failure among Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome infected (AIDS) children who were on Antiretroviral Therapy (ART) in Amhara National Regional State, Ethiopia. Methods: A retrospective follow-up study was conducted from January 2010 to March 2016. A total of 824 children under the age of 15 years who had started ART were included in the study. Data were collected from children's medical chart and ART registration logbook using a standard checklist. A Weibull regression model was used to identify the risk factors for treatment failure. Adjusted Hazard Ratios with 95% confidence intervals were used to declare statistical significance. Results: The mean (±SD) age of the children was 6.4 ± 3.6 years with a median (IQR) follow up of 30.5 (IQR: 14.6, 51.4) months. Sixty-three children (7.7%, 95%CI:5.8, 9.5) developed treatment failure. Seventeen (27.0%) of whom were immunological and 46 (73.0 %) clinical failures. The incidence rate of treatment failure was 22.1/10000 person-months. The cumulative probability of failure was 0.4 with 28562.5 person-month observations. Lack of disclosure [AHR=4. 4, 95%CI (1.8, 11.3)], opportunistic infections during initiation of ART [AHR= 2.3, 95% CI (1.3, 4.1)] and prolonged follow up [AHR = 0.06, 95% CI (0.02, 0.18)] were the main predictors of treatment failure. Conclusion: This study revealed that the incidence of treatment failure remains a significant public health concern in Ethiopia. Undisclosed HIV status to children, the presence of opportunistic infections during initiation of ART and prolonged follow up was found to be the main predictors of treatment failure. Hence, early detection of the treatment failures and further studies on viral monitor need to consider.
Supplementary analysis 2 for Vitamin D status during adolescence and the impact of lifestyle changes – two years follow-up from the Fit Futures Study
<p>Supplementary analysis 2: multiple regression model excluding those with recent UV-exposure.</p>
CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands
ClinicalTrials.gov study NCT07275489. IPD Sharing: YES. Countries: 1. Publications: 0.
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
ClinicalTrials.gov study NCT07046481. IPD Sharing: YES. Countries: 0. Publications: 10.
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
ClinicalTrials.gov study NCT02549352. IPD Sharing: NO. Countries: 1. Publications: 0.
Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study
ClinicalTrials.gov study NCT01599611. IPD Sharing: Not stated. Countries: 0. Publications: 1.
A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
ClinicalTrials.gov study NCT02247011. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Community-based Follow-up of Severely Malnourished Children
ClinicalTrials.gov study NCT01157741. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Long Term Follow-up of the VisAbility™ Micro Insert System for Presbyopic Patients
ClinicalTrials.gov study NCT03811249. IPD Sharing: NO. Countries: 1. Publications: 0.
The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study
ClinicalTrials.gov study NCT02848053. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI
ClinicalTrials.gov study NCT03099395. IPD Sharing: NO. Countries: 0. Publications: 1.
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
ClinicalTrials.gov study NCT01836042. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety Follow-Up to HP 802-247-09-015
ClinicalTrials.gov study NCT00900029. IPD Sharing: NO. Countries: 2. Publications: 0.
Cardiovascular Health Study (CHS) Events Follow-up Study
ClinicalTrials.gov study NCT00149435. IPD Sharing: Not stated. Countries: 0. Publications: 1.
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)
ClinicalTrials.gov study NCT01120379. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.